Updated long term and real world evidence on efficacy and safety
This is a must-read JDD article on brodalumab in plaque psoriasis. The review summarizes long term clinical trial findings, real world studies, and eight years of US pharmacovigilance data for this interleukin 17 receptor A blocker that was approved in 2017 for moderate to severe disease. Across trials and observational reports brodalumab is described as producing rapid skin clearance, high rates of complete response, and sustained disease control, including in patients who previously did not respond to other biologics. Integrated analyses and pharmacovigilance over the reported period did not identify new safety signals or demonstrated increases in malignancy, major adverse cardiac events, suicidal ideation or fatal adverse events. The review notes limitations inherent to trial follow up and passive surveillance and frames the findings as evidence supporting brodalumab as an effective, well tolerated option for moderate to severe plaque psoriasis.
This article provides a concise synthesis to inform treatment selection and patient discussions. Read the full JDD review for detailed trial summaries, real world cohorts, and the authors interpretation of safety monitoring.
J Drugs Dermatol. 2026;25(3):211-220. doi:10.36849/JDD.9739
Blog write-up assisted by AI
